Type 2 diabetes is a very serious problem of public health. Together with cardiovascular diseases, diabetes is responsible for most premature deaths all over the word. The latest guidelines prefer usage of antihyperglycaemic drugs with additional positive cardiovascular profile. DPP-4 inhibitors and vildagliptin among them for more than 10 years were studied also under those circumstances. In this article we will try to sum up the main studies as far as the cardiovascular safety of vildagliptin is concerned.